argenx (NASDAQ:ARGX) and Neon Therapeutics (NASDAQ:NTGN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, analyst recommendations and dividends.

Profitability

This table compares argenx and Neon Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
argenx N/A N/A N/A
Neon Therapeutics N/A -73.13% -65.66%

Analyst Recommendations

This is a summary of recent ratings and target prices for argenx and Neon Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
argenx 0 0 12 0 3.00
Neon Therapeutics 0 0 6 0 3.00

argenx presently has a consensus price target of $149.30, indicating a potential downside of 0.80%. Neon Therapeutics has a consensus price target of $17.00, indicating a potential upside of 311.62%. Given Neon Therapeutics’ higher possible upside, analysts clearly believe Neon Therapeutics is more favorable than argenx.

Earnings and Valuation

This table compares argenx and Neon Therapeutics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
argenx $25.37 million 190.86 -$78.70 million ($2.35) -64.05
Neon Therapeutics N/A N/A -$76.93 million ($5.54) -0.75

Neon Therapeutics has lower revenue, but higher earnings than argenx. argenx is trading at a lower price-to-earnings ratio than Neon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

68.0% of argenx shares are held by institutional investors. Comparatively, 69.6% of Neon Therapeutics shares are held by institutional investors. 38.9% of Neon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

About argenx

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Staten Biotechnology B.V.; and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.

About Neon Therapeutics

Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.